Skip to main content
PMC home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2023 May 16;14:1165212. doi: 10.3389/fphar.2023.1165212

Effect of tanshinone IIA for myocardial ischemia/reperfusion injury in animal model: preclinical evidence and possible mechanisms

Peng-Chong Zhu 1,†, Jiayi Shen 1,†, Ren-Yi Qian 1, Jian Xu 1, Chong Liu 1, Wu-Ming Hu 1, Ying Zhang 2, Ling-Chun Lv 1,*
PMCID: PMC10228700  PMID: 37261285

Abstract

Introduction: Tanshinone IIA (Tan IIA), the major active lipophilic ingredient of Radix Salviae Miltiorrhizae, exerts various therapeutic effects on the cardiovascular system. We aimed to identify the preclinical evidence and possible mechanisms of Tan IIA as a cardioprotective agent in the treatment of myocardial ischemia/reperfusion injury.

Methods: The study quality scores of twenty-eight eligible studies and data analyses were separately assessed using the CAMARADES 10-item checklist and Rev-Man 5.3 software.

Results: The study quality score ranged from 3/10 to 7/10 points. The present study provided preliminary preclinical evidence that Tan IIA could significantly decrease the myocardial infarct size, cardiac enzyme activity and troponin levels compared with those in the control group (p < 0.05).

Discussion: Tan IIA alleviated myocardial I/R injury via antioxidant, anti-inflammatory, anti-apoptosis mechanisms and improved circulation and energy metabolism. Thus, Tan IIA is a promising cardioprotective agent for the treatment of myocardial ischemia/reperfusion injury and should be further investigated in clinical trials.

Keywords: tanshinone IIA, myocardial ischemia/reperfusion injury, preclinical evidence, possible mechanisms, meta-analysis

1 Introduction

Acute myocardial infarction (MI) is serious consequence of coronary artery disease and the leading cause of death and disability worldwide (Ibáñez et al., 2015; Tsao et al., 2022). The most effective and well-established therapeutic strategy for treating acute MI patients is timely reperfusion by primary percutaneous coronary intervention or thrombolysis, which limits myocardial infarct size, preserves left ventricular systolic function and prevents the onset of heart failure (Bulluck et al., 2016). However, the process of restoring coronary blood flow to the ischemic myocardium can cause myocardial ischemia/reperfusion (I/R) injury, including reperfusion arrhythmias, the no-reflow phenomenon and myocardial stunning (Yellon and Hausenloy, 2007). Several mechanical and pharmacological therapies have been investigated to attenuate I/R injury over the past 30 years (Hausenloy and Yellon, 2013; Thind et al., 2015). Ischemic preconditioning and ischemic postconditioning are two major forms of mechanical strategies that apply transient episodes of myocardial ischemia and reperfusion either before or after the ischemic event, respectively, to protect the heart from I/R injury. (Hausenloy and Yellon, 2007). However, ischemic preconditioning (Heusch, 2013) is not feasible in the clinical setting because of the unpredictability of MI in patients, while the efficacy of ischemic postconditioning (Binder et al., 2015) is still inconclusive in clinical trials. In addition, pharmacological strategies failed to improve clinical trial outcomes (Frank et al., 2012; Perricone and Vander Heide, 2014; Ibáñez et al., 2015). Thus, a novel cardioprotective strategy is needed.

Radix Salviae Miltiorrhizae, the dried root and rhizome of Salvia miltiorrhiza Bge., a popular Chinese herbal medicine, has the function of activating blood flow circulation and dissipating blood stasis (Guo et al., 2020). It has been widely used in the treatment of various cardiovascular diseases for hundreds of years (Ansari et al., 2021). Tanshinone IIA (Tan IIA) (Figure 1), the major active lipophilic ingredient of Radix Salviae Miltiorrhizae, possesses antioxidant, anti-inflammatory (Kai et al., 2011), anti-apoptosis and anti-proliferative pharmacological properties (Shao et al., 2018; Luo et al., 2019). Systematic research reviews of animal studies provide important insights into the validity of animal studies, the precision of the estimated effects and the explanations of underlying mechanisms, and these reviews assist in the determination of whether a certain drug should be evaluated in human clinical trials (Roberts et al., 2002; Sandercock and Roberts, 2002; Briel et al., 2013). Therefore, we reviewed the available preclinical evidence and possible mechanisms of Tan IIA as a cardioprotective agent for myocardial I/R injury.

FIGURE 1.

FIGURE 1

Open in a new tab

Chemical structures of Tan IIA (C19H18O3, MW 294.34).

2 Methods

This review complied with the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) statement (Stewart et al., 2015).

2.1 Data sources and search strategy

We searched the following seven databases: PubMed, Cochrane Library, Embase, Wanfang database, China National Knowledge Infrastructure (CNKI), VIP database (VIP), and China Biology Medicine disc (CBM). The search time was limited from inception to the end of September 2022. The search terms used were “danshentong IIA OR tanshinone IIA OR tanshinone” AND “myocardial damage OR myocardial injury OR myocardial infarction OR myocardial ischemia OR myocardial ischemia reperfusion.” The reference lists of potential articles were hand-searched.

2.2 Eligibility criteria

To prevent bias, the inclusion criteria were as follows: 1) animal studies in vivo; 2) myocardial I/R model induced by coronary artery occlusion; 3) analyzed intervention received Tan IIA treatment only, comparator intervention received vehicle or no treatment; 4) primary outcomes were myocardial infarction (MI) size, cardiac enzymes or cardiac troponin T/I (cTnT/I) level, while secondary outcomes were serum indices or protein levels related to cardioprotection mechanisms. Studies in which other traditional Chinese medicines were administered with other additional pharmacological treatments, studies with no control group, duplicate publications and in vitro or ex vivo studies were excluded.

2.3 Data extraction

Data were extracted independently by two authors, and discrepancies were discussed in group consultation. The following details were recorded: the authors; study time; animal information (species, sex, number, and weight); and interventions, modeling methods, the dose of drugs, and outcomes. When various doses of the drug were used or outcomes were measured at different time points in trials, we adopted the highest dose and the final time measurements.

2.4 Risk of bias in individual studies

Quality evaluation of the included studies was conducted by the modified CAMARADES 10-point scoring scale (Macleod et al., 2004; Yu et al., 2017). The modifications are listed as follows: D, blinded induction of model; F, use of anesthetic without significant intrinsic cardioprotective activity; G, appropriate animal model (aged, diabetic, or hypertensive); disagreements were resolved through adjudication by the corresponding author.

2.5 Statistical analysis

Meta-analysis was performed using RevMan V.5.3 software. All data abstracted were classified into continuous variables and given an estimate of the combined overall effect sizes by utilizing the standard mean difference (SMD) or mean difference (MD) with the effects model. Heterogeneity and the choice of effects model were assessed using the Cochrane Q statistic test and the I2-statistic test. A fixed-effects model was selected when statistical heterogeneity was identified (heterogeneity test, if I 2 < 50% and p < 0.10), otherwise, a random effects model was used.

3 Results

After systematically searching the databases, 768 published articles were identified. According to the eligibility criteria, we excluded inappropriate studies, and 28 studies were ultimately included in the systematic review (Figure 2).

FIGURE 2.

FIGURE 2

Open in a new tab

Summary of the process for identifying candidate studies.

3.1 Characteristics of included studies

Twenty eight studies (19 studies in Chinese and 9 in English) were published between 1996 and 2021. Sprague‒Dawley (SD) rats, Wistar rats, male/female rabbits, male New-Zealand rabbits, and male/female Japan-Sino hybridization white rabbits were used in these studies. Modeling in these studies included ligation of the left anterior descending coronary artery (LAD), the left ventricular coronary artery (LVA), the left circumflex coronary artery (LCA) and the left marginal branch (LMB). The dosage of TanIIA varied between 3 mg•kg−1 and 70 mg•kg−1. Evaluated metrics included myocardial infarct size, myocardial cell apoptosis, arrhythmia score, lactate dehydrogenase (LDH), creatine kinase (CK), creatine kinase-MB (CK-MB), cTnI, superoxide dismutase (SOD), malondialdehyde (MDA), glutathione (GSH), glutathione peroxidase (GSH-Px), caspase-3, B-cell lymphoma-2 (Bcl-2), Bcl-2-Associated X (Bax), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), aspartate transaminase (AST), high mobility group box-1 protein (HMGB1), amplitude of T wave, ST-segment elevation, ejection fraction (EF), and fractional shorting (FS). The detailed characteristics of the studies are shown in Table 1.

TABLE 1.

Characteristics of the 28 included studies.

Study (years) Species (sex, n = experimental/control group) Weight Model (method) Anesthetic Treatment group (method to Tan IIA) Control group Outcome index (time) Intergroup differences
Ma et al., 2017 SD rats (male, 16/16) 180–220 g Ligation of LAD for 30 min then reperfusion for 180 min Phenobarbital Sodium (3%) Gavaged with Tan IIA (20 mg/kg*d), once a day, for 5 days, before establishing model Gavaged with isasteric normal saline, once a day, for 5 days, before establishing model 1. Infarct size (AAI/AAR) 1. p < 0.05
2. cTnI 2. p < 0.05
3. Cytc 3. p < 0.05
Dai et al., 2013 SD rats (male, 8/8) 240–320 g Ligation of LAD for 40 min then reperfusion for 120 min 20% urethane (5 mL/kg) Intravenous injected with Tan IIA (30 mg/kg), 3 min before reperfusion and 2 min after reperfusion Intravenous injected with nothing, 3 min before reperfusion and 2 min after reperfusion 1. Apoptosis index 1. p < 0.01
2. CK 2. p < 0.01
3. LDH 3. p < 0.01
4. SOD 4. p < 0.05
5. MDA 5. p < 0.05
Tang et al., 2017 SD rats (male, 10/10) 260–280 g Ligation of LAD for 30 min then reperfusion for 480 min 3% pentobarbital sodium (30 mg/kg) Intraperitoneal injected with Tan IIA (30 mg/kg), once a day, for 7 days, before establishing model Intraperitoneal injected with isasteric normal saline, once a day, for 7 days, before establishing model 1. SOD 1. p < 0.01
2. MDA 2. p < 0.01
3. CAT 3. p < 0.01
4. GSH-Px 4. p < 0.01
5. Nrf-2 5. p < 0.01
6. HO-1 6. p < 0.01
Zheng et al., 2010 SD rats (male, 10/10) 200–300 g Ligation of LAD for 60 min then reperfusion for 120 min Pentobarbital sodium (2.5%) Gavaged with Tan IIA (30 mg/kg*d), once a day, for 7 days, before establishing model Intravenous injected with isasteric normal saline, once a day, for 7 days, before establishing model 1. Apoptosis index 1. p < 0.05
2. Caspase-3 2. p < 0.05
3. Bcl-2 3. p < 0.01
Zhang and Zhang. 2010 Wistar rats (male/female, 20/20) Not mentioned Ligation of LAD for 30 min then reperfusion for 120 min Diethyl ether Gavaged with Tan IIA (15 mg/kg*d), once a day, for 3 days, before establishing model Gavaged with normal saline (5 mL/kg), once a day, for 3 days, before establishing model 1. Infarct size (AAI/LVA) 1. p < 0.05
2. CK 2. p < 0.05
3. LDH 3. p < 0.05
4. AST 4. p < 0.01
5. SOD 5. p < 0.01
6. MDA 6. p < 0.001
7. GSH-PX 7. p < 0.01
Han et al., 2016 SD rats (male, 8/8) 220–270 g Ligation of LAD for 30 min then reperfusion for 180 min Pentobarbital sodium (3%) Intraperitoneal injected with Tan IIA (40 mg/kg*d), once a day, for 7 days, before establishing model Intraperitoneal injected with isasteric distilled water, once a day, for 7 days, before establishing model 1. Apoptosis index 1. p < 0.05
2. P-Akt 2. p < 0.05
3. Mfn2 3. p < 0.05
Wu and He. 2012 SD rats (male, 10/10) 280–320 g Ligation of LAD for 30 min then reperfusion for 120 min 10% Chloral hydrate (300 mg/kg) Gavaged with Tan IIA (50 mg/kg*d), once a day, for 7 days, before establishing model Gavaged with normal saline (2 mL/d), once a day, for 7 days, before establishing model 1. Infarct size (AAI/LVA) 1. p < 0.05
2. HR 2. p < 0.05
Zhou and Yang. 2012 Wistar rats (male, 16/16) 250–300 g Ligation of LAD for 30 min then reperfusion for 60 min 3% pentobarbital sodium (0.15 mL/100 g) Intraperitoneal injected with Tan IIA (10 mg/kg) before establishing model Intraperitoneal injected with isasteric normal saline before establishing model 1. Infarct size (AAI weight/whole weight) 1. p < 0.01
2. Arrhythmia score 2. p < 0.01
3. NF-KB 3. p < 0.01
4. TNF-α 4. p < 0.01
Han. 2011 Wistar rats (male/female, 10/10) 150–250 g Ligation of LAD for 45 min then reperfusion for 120 min 20% Urethane (1 g/kg) Intraperitoneal injected with Tan IIA (16 mg/kg) before establishing model Intraperitoneal injected with normal saline (4 mL/kg) before establishing model 1. amplitude of T wave 1. p < 0.05
2. incidence of 2 h arrhythmia 2. p < 0.05
3. Bcl-2OD 3. p < 0.05
4. BaxOD 4. p < 0.05
5. Bcl-2/Bax 5. p < 0.05
Li et al., 2016a SD rats (male, 13/13) 210–250 g Ligation of LAD for 30 min then reperfusion for 120 min Pentobarbital sodium (60 mg/kg) Intravenous injected with Tan IIA (20 mg/kg), before establishing model Intravenous injected with nothing, before establishing model 1. Infarct size (AAI/AAR) 1. p < 0.05
2. Apoptosis index 2. p < 0.05
3. CK-MB 3. p < 0.05
4. LDH 4. p < 0.05
5. SOD 5. p < 0.05
6. MDA 6. p < 0.05
7. SDH 7. p < 0.05
8. COX 8. p < 0.05
9. H2O2 9. p < 0.05
Long et al., 2015 SD rats (male, 24/24) 200–250 g Ligation of LAD for 45 min then reperfusion for 72 h Pentobarbital sodium (40 mg/kg) Intravenous injected with Tan IIA (8 mg/kg), 30 min before establishing model and 24, 48 h after establishing model Intravenous injected with isasteric normal saline, 30 min before establishing model and 24, 48 h after establishing model 1. Infarct size (AAI/AAR) 1. p < 0.001
2. EF 2. p < 0.001
3. FS 3. p < 0.001
Pan et al., 2017 SD rats (male, 9/10) Not mentioned Ligation of LAD for 30 min then reperfusion for 24 h 10% Chloral hydrate (350 mg/kg) Intraperitoneal injected with Tan IIA (70 mg/kg), before establishing model Intraperitoneal injected with isasteric normal saline, before establishing model 1. Infarct size (AAI/AAR) 1. p < 0.05
2. Caspase-3 2. p < 0.05
3. Bcl-2 3. p < 0.05
4. Bax 4. p < 0.05
5. Beclin-1 5. p < 0.05
6. HMGB1 6. p < 0.05
Hu et al., 2015 SD rats (male, 10/10) 200–220 g Ligation of LAD for 30 min then reperfusion for 120 min Pentobarbital sodium (50 mg/kg) Intraperitoneal injected with Tan IIA (40 mg/kg*d), once a day, for 14 days, before establishing model Intraperitoneal injected with vehicle, once a day, for 14 days, before establishing model 1. Infarct size (AAI weight/whole weight) 1. p < 0.05
2. CK 2. p < 0.05
3. AST 3. p < 0.05
4. SOD 4. p < 0.05
5. GSH-Px 5. p < 0.05
6. MDA 6. p < 0.05
7. TNF-α 7. p < 0.05
8. IL-6 8. p < 0.05
9. iNOS 9. p < 0.05
10. HMGB1 10. p < 0.05
Wei et al., 2014 SD rats (male, 8/8) 250–300 g Ligation of LAD for 30 min then reperfusion for 24 h Pentobarbital sodium (50 mg/kg) Intravenous injected with Tan IIA (8 mg/kg), 4 h after reperfusion Intravenous injected with isasteric normal saline, 4 h after reperfusion 1. Infarct size (AAI/AAR) 1. p < 0.05
2. CK-MB 2. p < 0.05
3. AST 3. p < 0.05
4. LDH 4. p < 0.05
5. SOD 5. p < 0.05
6. MDA 6. p < 0.05
7. GSH-Px 7. p < 0.05
8. GSH 8. p < 0.05
Li et al., 2010 Wistar rats (male, 8/8) 250–300 g Ligation of LAD for 30 min then reperfusion for 60 min 10% Chloral hydrate (0.4 mL/100 g) Tail intravenous injected with Tan IIA (20 mg/kg), before establishing model Tail intravenous injected with nothing before establishing model 1. Arrhythmia score 1. p < 0.01
2. IL-6 2. p < 0.01
Fu et al., 2007 SD rats (male, 13/13) 280–300 g Ligation of LAD for 45 min then reperfusion for 240 min Diethyl ether Gavaged with Tan IIA (60 mg/kg*d), once a day, for 14 days, before establishing model Gavaged with 0.5% carboxymethyl cellulose sodium (10 mg/kg*d), once a day, for 14 days, before establishing model 1. SOD 1. p < 0.05
2. MDA 2. p < 0.05
3. Bcl-2 3. p < 0.05
4. Bax 4. p < 0.05
5. Caspase-3 5. p < 0.05
Zhang et al., 2010 SD rats (male, 20/20) 200–220 g Ligation of LAD for 30 min then reperfusion for 180 min 3% isoflurane Intraperitoneal injected with Tan IIA (5 mg/kg*d), once a day, for 7 days, before establishing model Intraperitoneal injected with isasteric normal saline, once a day, for 7 days, before establishing model 1. Infarct size (AAI/LVA) 1. p < 0.05
2. EF 2. p < 0.05
3. TNF-α 3. p < 0.05
4. IL-6 4. p < 0.05
5. Caspase-3 5. p < 0.05
6. P-Akt 6. p < 0.05
7. NF-KB 7. p < 0.05
Li et al., 2016b Wistar rats (male/female, 8/8) 130–230 g Ligation of LAD for 30 min then reperfusion for 30 min. This process was repeated 3 times 2% Pentobarbital sodium Tail intravenous injected with Tan IIA (2 mL/100 g*d), once a day, for 14 days, before establishing model Tail intravenous injected with isasteric normal saline, once a day, for 14 days, before establishing model 1. SOD 1. p < 0.05
2. MDA 2. p < 0.05
3. CAT 3. p < 0.05
4. VEGF 4. p < 0.05
5. HIF-1 5. p < 0.05
6. FLK-1 6. p < 0.05
Wang 2021 Wistar rats (male/female, 8/8) 355.62 ± 20.3 g Ligation of LAD for 45 min then reperfusion for 24 h 3% Pentobarbital sodium Intravenous injected with Tan IIA (20 mg/kg), before establishing model Intravenous injected with isasteric normal saline, before establishing model 1. AAI/AAR 1. p < 0.05
2. LDH 2. p < 0.05
3. apoptosis index 3. p < 0.05
4. ROS 4. p < 0.05
5. MDA 5. p < 0.05
6. SOD 6. p < 0.05
7. Bcl-2 7. p < 0.05
Li et al., 2017 SD rats (male, 9/9) 200–300 g Ligation of LAD for 30 min then reperfusion for 2 h Chloral hydrate Intraperitoneal injected with Tan IIA (2 mL/kg). The Tan IIA was administered once every other day for 8 weeks, after establishing model Intraperitoneal injected with normal saline (0.5 mL/kg). The normal saline was administered once every other day for 8 weeks, after establishing model 1. MDA 1. p < 0.05
2. SOD 2. p < 0.05
3. LDH 3. p < 0.05
4. Bax 4. p < 0.05
5. Bcl-2 5. p < 0.05
6. apoptosis index 6. p < 0.05
7. CTnI 7. p < 0.05
Shen et al., 2018 SD rats (male, 7/7) 200–210 g Ligation of LAD for 45 min then reperfusion for 2 h 10% chloral hydrate Gavaged with Tan IIA (7.912 mg/kg), before establishing model Gavaged with nothing, before establishing model 1. AAI/AAR 1. p < 0.05
2. LDH 2. p < 0.05
3. SOD 3. p < 0.05
4. MDA 4. p < 0.05
Tao et al., 1996 Rabbits (male/female, 10/10) Not mentioned Ligation of LAD for 30 min then reperfusion for 30 min 3% pentobarbital sodium Intravenous injected with Tan IIA (5 mg/kg), before reperfusion Intravenous injected with nothing, before reperfusion 1. SOD 1. p < 0.001
2. MDA 2. p < 0.001
Wang et al., 2016 New Zealand rabbits (male, 10/10) 2.2–2.7 Kg Ligation of LMB for 90 min then reperfusion for 120 min 3% Pentobarbital sodium (1.1 mL/kg) Intravenous injected with Tan IIA (5 mg/kg), before reperfusion Intravenous injected with 25% Glu (2 mL/kg), before reperfusion 1. Infarct size (AAI/LVA) 1. p < 0.05
2. CK 2. p < 0.05
3. CK-MB 3. p < 0.01
4. TNF-α 4. p < 0.05
Ai 2013 Rabbits (male/female, 10/10) 2.0–2.5 Kg Ligation of LCA for 30 min then reperfusion for 120 min 20% Urethane (5 mL/kg) Intravenous injected with Tan IIA (3 mg/kg), before establishing model Intravenous injected with nothing before establishing model 1. SOD 1. p < 0.05
2. MDA 2. p < 0.05
Wang et al., 2012 New Zealand rabbits (male, 10/10) 2.2–2.7 Kg Ligation of LMB for 90 min then reperfusion for 120 min 3% Pentobarbital sodium (1.1 mL/kg) Intravenous injected with Tan IIA (5 mg/kg), before reperfusion Intravenous injected with 25% Glu (2.0 mL/kg), before reperfusion 1. CTnI 1. p < 0.01
2. SOD 2. p < 0.05
Lin et al., 2013 New Zealand rabbits (male, 10/10) 2.5–3.0 Kg Ligation of LVA for 60 min then reperfusion for 120 min 3% Pentobarbital sodium (1.0 mL/kg) Intravenous injected with Tan IIA (4 mg/kg), before reperfusion Intravenous injected with isasteric normal saline, before reperfusion 1. Infarct size (AAI/LVA) 1. p < 0.05
2. ST -segment changes 2. p < 0.05
Wang et al., 2007 Japan-Sino hybridization whit e rabbits (male/female, 8/6) 2.28 ± 0.31 Kg Ligation of LCA for 40 min then reperfusion for 60 min Pentobarbital sodium (30 mg/kg) Intravenous injected with Tan IIA (3 mg/kg), before establishing model Intravenous injected with 25% Glu (1.0 mL/kg), before establishing model 1. CK 1. p < 0.01
2. LDH 2. p < 0.01
3. SOD 3. p < 0.05
4. GSH-Px 4. p < 0.05
5. MDA 5. p < 0.05
Liu et al., 2017 New Zealand rabbits (male/female, 10/10) 1.5–1.8 Kg Ligation of LCA for 30 min then reperfusion for 30 min. This process was repeated 3 times Pentobarbital sodium (1 mL/kg) Intravenous injected with Tan IIA (5 mL/kg*d), once a day, for 7 days, before establishing model Intravenous injected with isasteric normal saline, once a day, for 7 days, before establishing model 1. CK-MB 1. p < 0.05
2. LDH 2. p < 0.05
3. SOD 3. p < 0.05
Open in a new tab

Note: AAI, area at infarct; AAR, area at risk; AST, aspartate transaminase; Bcl-2, B-cell lymphoma-2; Bax, Bcl-2-Associated X; cTnI, cardiac troponin I; CytC, cytochrome C; CAT, catalase; CK, creatine kinase; CK-MB, creatine kinase-MB; COX, cytochrome c oxidase; EF, ejection fraction; FS, fractional shorting; Glu, glucose injection; GSH, glutathione synthetase; GSH-Px, glutathione peroxidase; HMGB1, high mobility group box-1 protein; HO-1, hemeoxygenase-1; iNOS, inducible nitric oxide synthase; IL-6, interleukin-6; LAD, the left anterior descending coronary artery; LMB, the left marginal branch; LCA, the left circumflex coronary artery; LVA, the left ventricular coronary artery; LVA, left ventricular area; LDH, lactate dehydrogenase; MDA, malondialdehyde; Nrf-2, nuclearfactor erythroid-2-related factor-2; Mfn2, mitofusin2; p-Akt, phosphothreonine kinase; SD rats, Sprague-Dawley; SOD, superoxide dismutase; TNF-α, tumor necrosis factor-α.

3.2 Study quality

The quality score of the studies ranged from 3 to 7. All studies were published in a peer-reviewed journal. They all described random allocation to treatment or control and used an anesthetic without substantial intrinsic vascular protection activity. Eleven studies (Fu et al., 2007; Fu et al., 2007; Zhang et al., 2010; Wei et al., 2014; Hu et al., 2015; Long et al., 2015; Li Q. et al., 2016; Li X. Y. et al., 2016; Liu et al., 2017; Pan et al., 2017; Tang et al., 2017) reported control of temperature. One study (Zhang et al., 2010) mentioned an appropriate animal model. Eleven studies (Fu et al., 2007; Fu et al., 2007; Zhang et al., 2010; Wei et al., 2014; Hu et al., 2015; Long et al., 2015; Li Q. et al., 2016; Li X. Y. et al., 2016; Liu et al., 2017; Pan et al., 2017; Tang et al., 2017) stated compliance with animal welfare regulations, and 10 studies (Fu et al., 2007; Fu et al., 2007; Zhang et al., 2010; Hu et al., 2015; Long et al., 2015; Li Q. et al., 2016; Li X. Y. et al., 2016; Pan et al., 2017; Li et al., 2019) a statement of potential conflicts of interest. None of the studies mentioned blinded induction of the model, blinded assessment of outcome or sample size calculation. The methodological quality is shown in Table 2.

TABLE 2.

Risk of bias of the included studies.

Study A B C D E F G H I J Total
Ma et al., 2017 √ √ √ 3
Dai et al., 2013 √ √ √ 3
Tang et al., 2017 √ √ √ √ √ √ 6
Zheng et al., 2010 √ √ √ 3
Zhang and Zhang. 2010 √ √ √ 3
Han et al., 2016 √ √ √ √ 4
Wu and He. 2012 √ √ √ √ 4
Zhou and Yang. 2012 √ √ √ √ 4
Han. 2011 √ √ √ 3
Li et al., 2016a √ √ √ √ √ √ 6
Long et al., 2015 √ √ √ √ √ √ 6
Pan et al., 2017 √ √ √ √ √ √ 6
Hu et al., 2015 √ √ √ √ √ √ 6
Wei et al., 2014 √ √ √ √ √ 5
Li et al., 2010 √ √ √ √ 4
Fu et al., 2007 √ √ √ √ √ √ 6
Zhang et al., 2010 √ √ √ √ √ √ √ 7
Li et al., 2016b √ √ √ √ √ √ 6
Wang 2021 √ √ √ 3
Li et al., 2017 √ √ √ √ 4
Shen et al., 2018 √ √ √ √ √ √ 6
Tao et al., 1996 √ √ √ 3
Wang et al., 2016 √ √ √ √ 4
Ai 2013 √ √ √ 3
Wang et al., 2012 √ √ √ √ 4
Lin et al., 2013 √ √ √ √ 4
Wang et al., 2007 √ √ √ 3
Liu et al., 2017 √ √ √ √ √ √ 6
Open in a new tab

Note: Studies fulfilling the criteria of: A: peer reviewed publication; B: control of temperature; C: random allocation to treatment or control; D: blinded induction of model; E: blinded assessment of outcome; F: use of anesthetic without significant intrinsic cardioprotective activity; G: appropriate animal model (aged, diabetic, or hypertensive); H: sample size calculation; I: compliance with animal welfare regulations; J: statement of potential conflict of interests. Compliant item was given one point using a tick to indicate.

3.3 Effectiveness

3.3.1 Primary outcome measures

3.3.1.1 Myocardial infarct size

Twelve studies (Zhang et al., 2010; Zhang and Zhang, 2010; Wu and He, 2012; Lin et al., 2013; Wei et al., 2014; Long et al., 2015; Li Q. et al., 2016; Wang et al., 2016; Ma et al., 2017; Pan et al., 2017; Shen et al., 2018; Wang, 2021) used myocardial infarct size as an outcome measure. Meta-analysis of 12 studies that the Tan IIA-treated group exhibited significantly decreased myocardial infarct size compared with that of the control group (n = 145, MD −0.13, 95% CI [−0.18 to −0.09], p < 0.00001; I 2 = 98%) (Figure 3). Owing to obvious heterogeneity, we conducted subgroup analysis according to the different calculation methods. 1) The meta-analysis of 5 studies (Zhang et al., 2010; Zhang and Zhang, 2010; Wu and He, 2012; Lin et al., 2013; Wang et al., 2016) showed that the Tan IIA-treated group exhibited a significantly decreased the area at infarct/left ventricular area (AAI/LVA) compared with that of the control group (n = 60, MD −0.05, 95% CI [−0.07 to −0.04], p = 0.07; I 2 = 55%) (Figure 4); The meta-analysis of 7 studies (Fu et al., 2007; Wei et al., 2014; Long et al., 2015; Li Q. et al., 2016; Ma et al., 2017; Shen et al., 2018; Wang, 2021) that Tan IIA significantly reduced the area at infarct/area at risk (AAI/AAR) (n = 76, MD −0.18, 95% CI [−0.20 to −0.15], p < 0.0001; I 2 = 83%) (Figure 4). Although the heterogeneity decreased after subgroup analysis, the heterogeneity in both subgroups was still high. Thus, further subgroup analysis was performed in the AAI/LVA and AAI/AAR groups. In the AAI/LVA studies, the different animal species (rats or rabbits) may have been the source of heterogeneity. The meta-analysis of 3 rats studies (Zhang et al., 2010; Zhang and Zhang, 2010; Wu and He, 2012) showed a significant effect of Tan IIA on decreasing the AAI/LVA (n = 40, MD −0.06, 95% CI [−0.07 to −0.05], p = 0.14; I 2 = 49%) (Figure 5), and the meta-analysis of 2 rabbit studies (Lin et al., 2013; Wang et al., 2016) showed similar results (n = 20, MD −0.04, 95% CI [−0.06 to −0.02], p = 0.24; I 2 = 26%) (Figure 5). In the AAI/AAR studies, different routes of administration (intravenous injection and gavage) may have been the source of heterogeneity. The meta-analysis of the 4 studies (Wei et al., 2014; Long et al., 2015; Li Q. et al., 2016; Wang, 2021) that used intravenous injection indicated a significant effect of Tan IIA on reducing the AAI/AAR (n = 53, MD −0.18, 95% CI [−0.19 to −0.18], p = 0.13; I 2 = 47%) (Figure 6), and the meta-analysis on the 2 studies (Ma et al., 2017; Shen et al., 2018) that used gavage administration showed similar results (n = 23, MD −0.12, 95% CI [−0.14 to −0.09], p = 0.23; I 2 = 30%) (Figure 6).

FIGURE 3.

FIGURE 3

Open in a new tab

The forest plot: effects of Tan IIA for decreasing the myocardial infarction size compared with control group.

FIGURE 4.

FIGURE 4

Open in a new tab

The forest plot: effects of Tan IIA for reducing the myocardial infarction size (area at infarct/left ventricular area, area at infarct/area at risk) compared with control group.

FIGURE 5.

FIGURE 5

Open in a new tab

The forest plot: effects of Tan IIA for reducing the myocardial infarction size in rats/rabbits compared with control group.

FIGURE 6.

FIGURE 6

Open in a new tab

The forest plot: effects of Tan IIA for reducing the myocardial infarction size in different routes of administration group compared with control.

3.3.1.2 Cardiac enzymes and troponin

The meta-analysis of 9 studies (Fu et al., 2007; Wang et al., 2007; Zhang and Zhang, 2010; Dai et al., 2013; Wei et al., 2014; Li Q. et al., 2016; Liu et al., 2017; Li et al., 2019; Wang, 2021) showed that the Tan IIA-treated group exhibited a significant decrease in LDH levels compared with those in the control group (n = 81, SMD −2.49, 95% CI [−2.94 to −2.04], p = 0.05; I 2 = 49%). As a result of the obvious heterogeneity, we conducted subgroup analysis according to the different animal species (rats or rabbits). The two rabbit studies (Wang et al., 2007; Liu et al., 2017) showed a significant effect of Tan IIA on decreasing LDH (n = 16, SMD −2.92, 95% CI [−3.96 to −1.87], p = 0.45; I 2 = 0%) (Figure 7). The seven rat studies (Fu et al., 2007; Zhang and Zhang, 2010; Dai et al., 2013; Wei et al., 2014; Li Q. et al., 2016; Li et al., 2019; Wang, 2021) showed a significant effect of Tan IIA on decreasing LDH (n = 63, SMD −2.39, 95% CI [−2.89 to −1.89], p = 0.03; I 2 = 58%). We performed a sensitivity analysis by sequentially excluding each study in the rat group. After removing one study (Zhang and Zhang, 2010) in which the dosage of Tan IIA administered before establishing the model was much higher than that in other studies, the meta-analysis of the remaining 6 rat studies (Fu et al., 2007; Dai et al., 2013; Wei et al., 2014; Li Q. et al., 2016; Li et al., 2019; Wang, 2021) showed that Tan IIA decreased LDH levels (n = 53, SMD −2.82, 95% CI [−3.40 to −2.23], p = 0.25; I 2 = 25%) (Figure 7). Three rat studies (Zhang and Zhang, 2010; Dai et al., 2013; Hu et al., 2015) used CK as the outcome metric. After removing the study (Dai et al., 2013) in which the ligation time was distinct from that in the other studies, the meta-analysis of the 2 remaining studies (Zhang and Zhang, 2010; Hu et al., 2015) showed that the Tan IIA-treated group exhibited significantly decreased CK levels compared with those in the control group (n = 20, SMD −0.89, 95% CI [−1.55 to−0.23], p = 0.68; I 2 = 0%) (Figure 8A). Moreover, the meta-analysis of 2 rabbit studies (Wang et al., 2007; Wang et al., 2016) showed that Tan IIA reduced CK levels (n = 18, SMD −1.51, 95% CI [−2.33 to −0.68], p = 0.31; I 2 = 4%) (Figure 8B). Two studies (Wei et al., 2014; Li Q. et al., 2016) showed that the Tan IIA-treated group had decrease CK-MB levels compared with those in the control group (n = 21, SMD −1.78, 95% CI [−2.53 to −1.03], p = 0.27; I 2 = 18%) (Figure 8C). The meta-analysis of 3 studies showed (Zhang and Zhang, 2010; Wei et al., 2014; Hu et al., 2015) that the Tan-IIA treated group exhibited significantly reduced AST levels compared with those in the control group (n = 28, SMD −1.23, 95% CI [−1.81 to −0.66], p = 0.84; I 2 = 0%) (Figure 8D). One study (Ma et al., 2017) used cTnI as the outcome measure and showed that the Tan IIA-treated group exhibited decreased cTnI levels compared with those in the control group (p < 0.05).

FIGURE 7.

FIGURE 7

Open in a new tab

The forest plot: effects of Tan IIA for decreasing lactate dehydrogenase in rats/rabbits compared with control group.

FIGURE 8.

FIGURE 8

Open in a new tab

The forest plot: effects of Tan IIA for decreasing creatine kinase (A) rats group; (B) rabbits group; (C) creatine kinase-MB; (D) aspartate transaminase compared with control group.

3.3.1.3 The level of ST-segment elevation and cardiac function

One study (Li et al., 2019) reported that compared to the control, Tan IIA can reduce ST-segment elevation (p < 0.05) and 2 studies (Zhang et al., 2010; Long et al., 2015) showed that Tan IIA-treated group had significantly improved left ventricular ejection fraction (LVEF) compared with that in the control group (p < 0.05).

3.3.2 Secondary outcome measures

The meta-analysis of 9 studies (Fu et al., 2007; Fu et al., 2007; Zhang and Zhang, 2010; Dai et al., 2013; Wei et al., 2014; Hu et al., 2015; Li Q. et al., 2016; Tang et al., 2017; Wang, 2021) showed that the Tan IIA-treated group rats exhibited significantly increased SOD levels compared to those in control group rats (n = 87, SMD 1.46, 95% CI [0.96 to 1.96]; p = 0.05; I 2 = 49%) (Figure 9A); 4 studies (Wang et al., 2007; Tan et al., 1996; Wang et al., 2012; Ai, 2013; Wang et al., 2016; Li et al., 2019) showed that Tan IIA increased the SOD levels in rabbits (n = 38, SMD 1.80, 95% CI [1.14 to 2.47], p = 0.25; I 2 = 27%) (Figure 9B); 13 studies (Tao et al., 1996; Fu et al., 2007; Wang et al., 2007; Zhang and Zhang, 2010; Ai, 2013; Dai et al., 2013; Wei et al., 2014; Hu et al., 2015; Li Q. et al., 2016; Liu et al., 2017; Tang et al., 2017; Shen et al., 2018; Wang, 2021) showed that Tan IIA reduced MDA levels (n = 137, SMD −3.40, 95% CI [−4.39 to −2.41]; p < 0.00001; I 2 = 85%); 5 studies (Zhang and Zhang, 2010; Wang et al., 2012; Wei et al., 2014; Hu et al., 2015; Tang et al., 2017) showed that Tan IIA increased GSH-Px levels; 5 studies (Zheng et al., 2010; Dai et al., 2013; Li Q. et al., 2016; Han et al., 2016; Wang, 2021) that Tan IIA decreased the myocardial cell apoptotic index; 4 studies (Fu et al., 2007; Zhang et al., 2010; Zheng et al., 2010; Pan et al., 2017) showed that Tan IIA reduced caspase-3 levels (p < 0.05); 1 study (Li Q. et al., 2016) showed that Tan IIA increased the expression levels of PI3K (p < 0.05) and p-Akt/Akt ratio; 1 study (Han et al., 2016) showed that Tan IIA increased the expression levels of p-Akt (p < 0.05); 4 studies (Zhang et al., 2010; Zhou and Yang, 2012; Hu et al., 2015; Wang et al., 2016) showed that Tan IIA reduced TNF-α levels (p < 0.05); 2 studies (Hu et al., 2015; Pan et al., 2017) showed that Tan IIA reduced HMGB1 levels; 3 studies showed that Tan IIA increased the ratio of Bcl-2/Bax proteins (Fu et al., 2007; Han, 2011; Pan et al., 2017). A schematic of the studied mechanisms by which Tan IIA protects against myocardial I/R injury is provided (Figure 10).

FIGURE 9.

FIGURE 9

Open in a new tab

The forest plot: effects of Tan IIA for increasing superoxide dismutase compared with control group. (A) Rats group; (B) rabbits group.

FIGURE 10.

FIGURE 10

Open in a new tab

A schematic representation of cardioprotective mechanisms of Tan IIA for myocardial ischemia/reperfusion injury.

4 Discussion

4.1 Summary of the evidence

The present study demonstrated that Tan IIA exerted potential cardioprotective functions mainly through antioxidant, anti-inflammatory, and anti-apoptosis mechanisms and improved circulation and energy metabolism in myocardial I/R models.

4.2 Limitations

There are several limitations that should be considered. First, a certain degree of selective bias is inevitable because the search strategy was limited to Chinese and English databases (Nolting et al., 2012), and negative findings are rarely published (Franco et al., 2014). Second, no study mentioned calculation of sample size, blinding of model establishment and outcome measurement. Moderate methodological quality will affect the accuracy of the results (Landis et al., 2012). Third, MI generally occurs in patients with comorbidities such as old age, diabetes or hypertension (Blankstein et al., 2012), and only 1 study (Zhang et al., 2010) constructed an animal model in diabetic rats. Finally, some studies used only female animals. The sensitivity and responses of animals of different sexes to the same drug or stimuli are quite different, especially in the cardiovascular system, which could interfere with the experimental results (Barp et al., 2002; Bae and Zhang, 2005).

4.3 Implications

Systematic reviews of animal studies can contribute to the improvement in the methodological quality of experiments (de Vries et al., 2014). In the present study, the methodological quality was moderate. Most of the deducted points were because of failures in sample size calculation and blinding in group allocation and outcome assessment, which are considered the core standards of research design. Studies with a lower quality tended to show better outcomes, resulting in global overestimation of the effect (García-Bonilla et al., 2012). For animal research, the “Reporting in vivo experiments (ARRIVE) guidelines” (Kilkenny et al., 2012) were proposed and are continuously improved to provide guidance on the complete and transparent reporting of in vivo animal research and to improve the quality of research reports. Thus, it is suggested that higher quality study design and reporting for Tan IIA should be executed according to the ARRIVE guidelines. Moreover, some aspects, such as calculation of sample size and blinding of group allocation and outcome assessment, should be specifically focused on.

In the present study, the vast majority of the included studies used young and healthy animals. However, in contrast to these young and healthy animal models, patients with MI usually have multiple cardiovascular risk factors and comorbidities, such as hypertension, hyperlipidemia, diabetes, hyperglycemia, heart failure, altered coronary circulation, and aging (Ferdinandy et al., 2014). These cardiovascular risks and comorbidities need to be treated in both the short and long term and contribute to the development of IR injury and complicate therapy (Rossello and Yellon, 2016). In addition, inappropriate selection of animal models could contribute to spurious or inconsistent results as well as unnecessary animal use (Lecour et al., 2014). Therefore, we propose the following suggestions: 1) choosing animal models that have similar anatomy and physiology to those of humans; 2) experiments with animal models that include risk factors and comorbidities; and 3) setting endpoints of animal studies closely resembling clinical settings. Furthermore, inconsistencies were particularly obvious in congenital heart disease (CHD) studies that used animals of different sexes (Barrett-Connor, 2013). Estrogen has been observed to have a cardioprotective effect both in clinical and preclinical studies, although the specific mechanism remains to be explored (Menazza et al., 2017). We suggest that sex differences in animals should be considered in experimental design.

Infarct size is the most robust primary outcome that is invariably used in animal experimental studies to evaluate the efficacy of various pharmacological or non-pharmacological strategies in preventing reperfusion injury, and it is usually analyzed after a short-term reperfusion or after a few days in an acute experiment (Ndrepepa et al., 2017). However, it is rarely tested clinically due to the limited diagnostic means, which is not helpful for intuitively evaluating the effect of different treatment strategies on cardiac function and determining the prognosis of patients. With the development of single-photon emission computed tomography (SPECT) and cardiac magnetic resonance (CMR), we propose that patients with acute coronary syndrome, especially ST-segment elevation myocardial infarction (STEMI), should be have their infarct size measured (Gibbons and Araoz, 2016) to stratify the risk of heart failure in patients and develop appropriate treatment strategies.

Recorded in the famous Traditional Chinese Medicine Classic “Compendium of Materia Medica,” the function of S. miltiorrhiza is described as invigorating the circulation of blood, dredging the collateral vessels on the pericardium and heart surface and treating colic. As the major active lipophilic ingredient of S. miltiorrhiza, Tan IIA is considered as the main contributor to the above efficacy. In Chinese medicine theory, it is used as a drug for promoting blood circulation and resolving blood stasis for cardiovascular ischemic diseases. However, the molecular and biological mechanisms of the cardioprorective effects of Tan IIA have not been fully elucidated. Experimental research has shown that myocardial I/R injury is related to several pathophysiological features, including the inflammatory response, endothelial dysfunction, generation of oxygen free radicals, mitochondrial dysfunction, myocardial cell apoptosis and autophagy (Heusch and Gersh, 2017). According to the present study, the possible mechanisms through which Tan IIA prevents myocardial I/R injury are as follows: 1) Anti-apoptosis: Tan IIA can increase the ratio of Bcl-2/Bax, downregulate the protein expression of Bax, decrease the expression level of caspase-3, upregulate autophagic markers (Beclin-1 and the ratio of LC3B/LC3A) and downregulate the expression of Mfn2, leading to anti-apoptosis effects against myocardial I/R injury by regulating the PI3K/AKT/mTOR, Ras-PI3K/Akt, JNK, ERK1/2, and PI3K/Akt/FOXO3A/Bim pathways. 2) Improving energy metabolism: Tan IIA can increase glucose oxidation; augment ATP restoration and production; improve the activities of Na+/K+-ATPase, Ca 2+ -ATPase and Mg 2+ -ATPase; alleviate the consumption of energy charge; reverse Ca 2+ overload; and protect the function of mitochondria. 3) Antioxidation: Tan IIA can promote the process of oxidative phosphorylation; increase the levels of antioxidants such as SOD, SDH, COX, GSH-Px, and CAT; and increase the release of NO, which simultaneously reduces free radical generation such as reactive oxidative species (O2-, HO-, and H2O2); Tan IIA also regulates the mitochondrial permeability transition pore (MTPT), suppresses chondriokinesis, and reduces the release of cytochrome c and malondialdehyde (MDA), resulting in antioxidation effects against myocardial I/R injury by regulating the Nrf2/ARE/HO-1, Ras/MAPK, and PI3K/Akt signaling pathways. 4) Anti-inflammation: Tan IIA can inhibit the expression of inflammation-related cytokines, such as IL-1, IL-6, TNF-α, and ICAM-1; upregulate the expression of EPOR; decrease the activation of NF-κB (p50 and p65); inhibit FGL2 and MPO expression; ameliorate microvascular obstruction (MVO); downregulate the mRNA expression of iNOS; and downregulate HMGB1 expression, leading to an anti-inflammatory effect against myocardial I/R injury by activating NF-κB and regulating the JAK2/STAT5 and FGL2-thrombin/PAR-1 pathways. 5) Improve circulation: Tan IIA can promote the expression of VEGF and EPO and facilitate the proliferation and differentiation of vascular cells to help vascular repair by the PI3K-Akt/mTOR and HIF-1α/VEGF pathways.

4.5 Conclusion

Tan IIA exerts cardioprotective function in myocardial I/R injury mainly through antioxidant, anti-inflammatory, and anti-apoptosis mechanisms and improving the circulation and energy metabolism. Thus, Tan IIA is a promising cardioprotective agent that should be further tested in MI clinical trials.

Funding Statement

This project was supported by the grant of Zhejiang Traditional Chinese Medicine Research Fund Project (2022ZB405).

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

JS, R-YQ, and P-CZ: study conception and design. P-CZ, JX, CL, W-MH, and YZ: acquisition, analysis, and/or interpretation of data. P-CZ and L-CL: final approval and overall responsibility for this published work.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  1. Ai D. (2013). Protective role of tanshinone IIA in cardiac function of ischemic-reperfused rabbits and its mechanism. J. Hubei Univ. Sci. Technol. Med. Sci. 27, 465–468. [Google Scholar]
  2. Ansari M. A., Khan F. B., Safdari H. A., Almatroudi A., Alzohairy M. A., Safdari M., et al. (2021). Prospective therapeutic potential of Tanshinone IIA: An updated overview. Pharmacol. Res. 164, 105364. 10.1016/j.phrs.2020.105364 [DOI] [PubMed] [Google Scholar]
  3. Bae S., Zhang L. (2005). Gender differences in cardioprotection against ischemia/reperfusion injury in adult rat hearts: Focus on akt and protein kinase C signaling. J. Pharmacol. Exp. Ther. 315, 1125–1135. 10.1124/jpet.105.090803 [DOI] [PubMed] [Google Scholar]
  4. Barp J., Araújo A. S., Fernandes T. R., Rigatto K. V., Llesuy S., Belló-Klein A., et al. (2002). Myocardial antioxidant and oxidative stress changes due to sex hormones. Braz. J. Med. 35, 1075–1081. 10.1590/s0100-879x2002000900008 [DOI] [PubMed] [Google Scholar]
  5. Barrett-Connor E. (2013). Gender differences and disparities in all-cause and coronary heart disease mortality: Epidemiological aspects. Clin. Endocrinol. metabolism 27, 481–500. 10.1016/j.beem.2013.05.013 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Binder A., Ali A., Chawla R., Aziz H. A., Abbate A., Jovin I. S. (2015). Myocardial protection from ischemia-reperfusion injury post coronary revascularization. Expert Rev. Cardiovasc. Ther. 13, 1045–1057. 10.1586/14779072.2015.1070669 [DOI] [PubMed] [Google Scholar]
  7. Blankstein R., Ahmed W., Bamberg F., Rogers I. S., Schlett C. L., Nasir K., et al. (2012). Comparison of exercise treadmill testing with cardiac computed tomography angiography among patients presenting to the emergency room with chest pain: The rule out myocardial infarction using computer-assisted tomography (ROMICAT) study. Cardiovasc. imaging 5, 233–242. 10.1161/CIRCIMAGING.111.969568 [DOI] [PubMed] [Google Scholar]
  8. Briel M., Müller K. F., Meerpohl J. J., von Elm E., Lang B., Motschall E., et al. (2013). Publication bias in animal research: A systematic review protocol. Syst. Rev. 2, 23. 10.1186/2046-4053-2-23 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bulluck H., Yellon D. M., Hausenloy D. J. (2016). Reducing myocardial infarct size: Challenges and future opportunities. Heart (British Card. Soc. 102, 341–348. 10.1136/heartjnl-2015-307855 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dai N. H., Chen W., Zheng Z. F., Zang Q. W. (2013). The protective effect of tanshinon 1I A postconditioning on myocardial ischemica/reperfusion injury in rats. Chin. J. Cardiovasc. Res. 11 (5), 549–551. [Google Scholar]
  11. de Vries R. B., Wever K. E., Avey M. T., Stephens M. L., Sena E. S., Leenaars M. (2014). The usefulness of systematic reviews of animal experiments for the design of preclinical and clinical studies. ILAR J. 55, 427–437. 10.1093/ilar/ilu043 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Ferdinandy P., Hausenloy D. J., Heusch G., Baxter G. F., Schulz R. (2014). Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol. Rev. 66, 1142–1174. 10.1124/pr.113.008300 [DOI] [PubMed] [Google Scholar]
  13. Franco A., Malhotra N., Simonovits G. (2014). Social science. Publication bias in the social sciences: Unlocking the file drawer. Sci. (New York, N.Y.) 345, 1502–1505. 10.1126/science.1255484 [DOI] [PubMed] [Google Scholar]
  14. Frank A., Bonney M., Bonney S., Weitzel L., Koeppen M., Eckle T. (2012). Myocardial ischemia reperfusion injury: From basic science to clinical bedside. Seminars Cardiothorac. Vasc. Anesth. 16, 123–132. 10.1177/1089253211436350 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fu J., Huang H., Liu J., Pi R., Chen J., Liu P. (2007). Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur. J. Pharmacol. 568, 213–221. 10.1016/j.ejphar.2007.04.031 [DOI] [PubMed] [Google Scholar]
  16. García-Bonilla L., Campos M., Giralt D., Salat D., Chacón P., Hernández-Guillamon M., et al. (2012). Evidence for the efficacy of statins in animal stroke models: A meta-analysis. J. Neurochem. 122, 233–243. 10.1111/j.1471-4159.2012.07773.x [DOI] [PubMed] [Google Scholar]
  17. Gibbons R. J., Araoz P. (2016). Does infarct size matter? J. Am. Coll. Cardiol. 67, 1684–1686. 10.1016/j.jacc.2016.02.022 [DOI] [PubMed] [Google Scholar]
  18. Guo R., Li L., Su J., Li S., Duncan S. E., Liu Z., et al. (2020). Pharmacological activity and mechanism of tanshinone IIA in related diseases. Drug Des. Dev. Ther. 14, 4735–4748. 10.2147/DDDT.S266911 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Han D. (2011). Study the effect of tanshinone IIA on apoptosis of myocardial cells of ischemia -reperfusion rats. Mod. Prev. Med. 38, 2572–2574. [Google Scholar]
  20. Han P., Feng J., Chen H. W. (2016). The effect of tanshinone II A on cardiomyocyte apoptosis after myocardial lschemia/reperfusion injury in rats. ZHONGGUO ZHONGYI JIZHENG 25, 1844–1846+1873. [Google Scholar]
  21. Hausenloy D. J., Yellon D. M. (2013). Myocardial ischemia-reperfusion injury: A neglected therapeutic target. J. Clin. investigation 123, 92–100. 10.1172/JCI62874 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Hausenloy D. J., Yellon D. M. (2007). Preconditioning and postconditioning: United at reperfusion. Pharmacol. Ther. 116, 173–191. 10.1016/j.pharmthera.2007.06.005 [DOI] [PubMed] [Google Scholar]
  23. Heusch G. (2013). Cardioprotection: Chances and challenges of its translation to the clinic. Lancet (London, Engl. 381, 166–175. 10.1016/S0140-6736(12)60916-7 [DOI] [PubMed] [Google Scholar]
  24. Heusch G., Gersh B. J. (2017). The pathophysiology of acute myocardial infarction and strategies of protection beyond reperfusion: A continual challenge. Eur. heart J. 38, 774–784. 10.1093/eurheartj/ehw224 [DOI] [PubMed] [Google Scholar]
  25. Hu H., Zhai C., Qian G., Gu A., Liu J., Ying F., et al. (2015). Protective effects of tanshinone IIA on myocardial ischemia reperfusion injury by reducing oxidative stress, HMGB1 expression, and inflammatory reaction. Pharm. Biol. 53, 1752–1758. 10.3109/13880209.2015.1005753 [DOI] [PubMed] [Google Scholar]
  26. Ibáñez B., Heusch G., Ovize M., Van de Werf F. (2015). Evolving therapies for myocardial ischemia/reperfusion injury. J. Am. Coll. Cardiol. 65, 1454–1471. 10.1016/j.jacc.2015.02.032 [DOI] [PubMed] [Google Scholar]
  27. Kai G., Xu H., Zhou C., Liao P., Xiao J., Luo X., et al. (2011). Metabolic engineering tanshinone biosynthetic pathway in Salvia miltiorrhiza hairy root cultures. Metab. Eng. 13, 319–327. 10.1016/j.ymben.2011.02.003 [DOI] [PubMed] [Google Scholar]
  28. Kilkenny C., Browne W. J., Cuthi I., Emerson M., Altman D. G. (2012). Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. Veterinary Clin. pathol. 41, 27–31. 10.1111/j.1939-165X.2012.00418.x [DOI] [PubMed] [Google Scholar]
  29. Landis S. C., Amara S. G., Asadullah K., Austin C. P., Blumenstein R., Bradley E. W., et al. (2012). A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490, 187–191. 10.1038/nature11556 [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Lecour S., Bøtker H. E., Condorelli G., Davidson S. M., Garcia-Dorado D., Engel F. B., et al. (2014). ESC working group cellular biology of the heart: Position paper: Improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc. Res. 104, 399–411. 10.1093/cvr/cvu225 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Li L. J., Jia J. H., Sun X. G., Fh Z. (2010). Influence of dingxin recipe and tanshinone IIA on IL-6 level in rat model of myocardial ischemia/reperfusion injury. J. GUIYANG Med. Coll. 35, 118–122. [Google Scholar]
  32. Li M., Wang Z. J., Liu J. Y., Qin L. (2019). Regulatory effect of sodium tanshinone IIA sulfonate on cardiac function and immune response in rats with myocardial ischemia-reperfusion injury. Chin. J. Clin. Anat. 37, 397–402. [Google Scholar]
  33. Li Q., Shen L., Wang Z., Jiang H. P., Liu L. X. (2016a). Tanshinone IIA protects against myocardial ischemia reperfusion injury by activating the PI3K/Akt/mTOR signaling pathway. Biomed. Pharmacother. = Biomedecine Pharmacother. 84, 106–114. 10.1016/j.biopha.2016.09.014 [DOI] [PubMed] [Google Scholar]
  34. Li X. Y., Du C. F., Xiao M., Xia J. L., Zhao J., He H. Q. (2016b). Effect of sodium sulfonate IIA sulfonate injection on VEGF of rats with acute myocardial ischemia preconditioning. WORLD Chin. Med. 11, 2105–2108. [Google Scholar]
  35. Lin D. M., Huang S. W., Lu M., Cen M. Q., Dou L. P., Wang L. L. (2013). Effect of tanshinon IIA on No-reflow after reperfusion of acute myocardial infarction in rabbits. Chin. ARCHIVES TRADITIONAL Chin. Med. 31, 1649–1651+1740. [Google Scholar]
  36. Liu J. J., Wu S., Li L. Z., Ao J. B. (2017). Protective effect of danshen A sodium sulfonate injection on vascular endothelial injury after ischemic preconditioning in rabbits with myocardial ischemia preconditioning. WORLD Chin. Med. 12, 618–622. [Google Scholar]
  37. Long R., You Y., Li W., Jin N., Huang S., Li T., et al. (2015). Sodium tanshinone IIA sulfonate ameliorates experimental coronary no-reflow phenomenon through down-regulation of FGL2. Life Sci. 142, 8–18. 10.1016/j.lfs.2015.10.018 [DOI] [PubMed] [Google Scholar]
  38. Luo H., Vong C. T., Chen H., Gao Y., Lyu P., Qiu L., et al. (2019). Naturally occurring anti-cancer compounds: Shining from Chinese herbal medicine. Chin. Med. 14, 48. 10.1186/s13020-019-0270-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Ma C. X., Sun Y., Chen X. B., Zhang L. (2017). Effects of tanshinone IIA preconditioning on myocardial ischemia reperfusion injury. SHANXI YIXUE ZAZHI 46, 1358–1359. [Google Scholar]
  40. Macleod M. R., O'Collins T., Howells D. W., Donnan G. A. (2004). Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 35, 1203–1208. 10.1161/01.STR.0000125719.25853.20 [DOI] [PubMed] [Google Scholar]
  41. Menazza S., Sun J., Appachi S., Chambliss K. L., Kim S. H., Aponte A., et al. (2017). Non-nuclear estrogen receptor alpha activation in endothelium reduces cardiac ischemia-reperfusion injury in mice. J. Mol. Cell. Cardiol. 107, 41–51. 10.1016/j.yjmcc.2017.04.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Ndrepepa G., Colleran R., Kastrati A. (2017). Reperfusion injury in ST-segment elevation myocardial infarction: The final frontier. Coron. artery Dis. 28, 253–262. 10.1097/MCA.0000000000000468 [DOI] [PubMed] [Google Scholar]
  43. Nolting A., Perleth M., Langer G., Meerpohl J. J., Gartlehner G., Kaminski-Hartenthaler A., et al. (2012). GRADE guidelines: 5. Rating the quality of evidence: Publication bias. Z. fur Evidenz, Fortbild. Qual. im Gesundheitswes. 106, 670–676. 10.1016/j.zefq.2012.10.015 [DOI] [PubMed] [Google Scholar]
  44. Pan Y., Qian J. X., Lu S. Q., Chen J. W., Zhao X. D., Jiang Y., et al. (2017). Protective effects of tanshinone IIA sodium sulfonate on ischemia-reperfusion-induced myocardial injury in rats. Iran. J. basic Med. Sci. 20, 308–315. 10.22038/ijbms.2017.8361 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Perricone A. J., Vander Heide R. S. (2014). Novel therapeutic strategies for ischemic heart disease. Pharmacol. Res. 89, 36–45. 10.1016/j.phrs.2014.08.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Roberts I., Kwan I., Evans P., Haig S. (2002). Does animal experimentation inform human healthcare? Observations from a systematic review of international animal experiments on fluid resuscitation. BMJ Clin. Res. ed.) 324, 474–476. 10.1136/bmj.324.7335.474 [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Rossello X., Yellon D. M. (2016). Cardioprotection: The disconnect between bench and bedside. Circulation 134, 574–575. 10.1161/CIRCULATIONAHA.116.022829 [DOI] [PubMed] [Google Scholar]
  48. Sandercock P., Roberts I. (2002). Systematic reviews of animal experiments. Lancet (London, Engl. 360, 586. 10.1016/S0140-6736(02)09812-4 [DOI] [PubMed] [Google Scholar]
  49. Shao H., Li M., Chen F., Chen L., Jiang Z., Zhao L. (2018). The efficacy of danshen injection as adjunctive therapy in treating angina pectoris: A systematic review and meta-analysis. Heart, lung circulation 27, 433–442. 10.1016/j.hlc.2017.10.016 [DOI] [PubMed] [Google Scholar]
  50. Shen W. L., Yu F., Xu L., Chen C., Cao Y. N., Liu S., et al. (2018). Protective effects of tanshinone IIA derivative on myocardial ischemia/reperfusion injury in rats. J. Chin. Pharm. Sci. 27, 1–13. 10.5246/jcps.2018.01.001 [DOI] [Google Scholar]
  51. Stewart L. A., Clarke M., Rovers M., Riley R. D., Simmonds M., Stewart G., et al. (2015). Preferred reporting items for systematic review and meta-analyses of individual participant data: The PRISMA-IPD statement. Jama 313, 1657–1665. 10.1001/jama.2015.3656 [DOI] [PubMed] [Google Scholar]
  52. Tang S. M., Wu Y. M., Zhou Y. T., Li X. Y., Meng X. B., Zhang H. (2017). The protective effect of Tanshinone IIA on oxidative stress induced by myocardial ischemia reperfusion iniury of rats. China Med. Her. | Chin. Med. Her. 14, 8–11. [Google Scholar]
  53. Tao J., Wang Z. Q., Liu Q. Y., Fang G. X. (1996). Sodium Tonshione IIA sulfonat against myocardial reperfusion injury. Shijiazhuang City of Hebei Province: Chinese joural of Anesthesiology, 202–204. [Google Scholar]
  54. Thind G. S., Agrawal P. R., Hirsh B., Saravolatz L., Chen-Scarabelli C., Narula J., et al. (2015). Mechanisms of myocardial ischemia-reperfusion injury and the cytoprotective role of minocycline: Scope and limitations. Future Cardiol. 11, 61–76. 10.2217/fca.14.76 [DOI] [PubMed] [Google Scholar]
  55. Tsao C. W., Aday A. W., Almarzooq Z. I., Alonso A., Beaton A. Z., Bittencourt M. S., et al. (2022). Heart disease and stroke statistics-2022 update: A report from the American heart association. Circulation 145, e153–e639. 10.1161/CIR.0000000000001052 [DOI] [PubMed] [Google Scholar]
  56. Wang H., Jiang Y. Q., Song G. Y., Zhang Z. L., Ma Y. Q. (2007). Influences of sodium tanshinone IIA on lipidperoxidation of myocardial ischemia reperfusion injury in rabbits. Chin. J. Gerontology, 2095–2097. [Google Scholar]
  57. Wang L. L., Hang S. W., Dou L. P., Che Q., Lu M., Wang Y., et al. (2012). Beneficial effects and the potential oxidative stress mechanism of tanshinone IIA on the No-reflow phenomenon in rabbits after acute myocardial infarction and reperfusion. Chin. ARCHIVES TRADITIONAL Chin. Med. 30, 2513–2516+2601. [Google Scholar]
  58. Wang L. L., Huang S. W., Dou L. P., Lu M., Hu P. F., Bo G., et al. (2016). Cardiac protective effect of tanshinone IIA sodium sulfonate on rabbit model of myocardial infarction reperfusion with No-reflow. Chin. ARCHIVES TRADITIONAL Chin. Med. 34, 678–682. [Google Scholar]
  59. Wang Y. (2021). Protective effect of tanshinone IIA on myocardial ischemia-reperfusion injury and its effect on JAK2/STAT3 pathway. Chin. J. Integr. Med. Cardio-/Cerebrovascuiar Dis. 19, 1290–1296. [Google Scholar]
  60. Wei B., Li W. W., Ji J., Hu Q. H., Ji H. (2014). The cardioprotective effect of sodium tanshinone IIA sulfonate and the optimizing of therapeutic time window in myocardial ischemia/reperfusion injury in rats. Atherosclerosis 235, 318–327. 10.1016/j.atherosclerosis.2014.05.924 [DOI] [PubMed] [Google Scholar]
  61. Wu X. Q., He L. S. (2012). Effect of Tanshinone IIA pretreatment on myocardial ischemia/reperfusion injury in rats. J. Trop. Med. 12, 917–919+912. [Google Scholar]
  62. Yellon D. M., Hausenloy D. J. (2007). Myocardial reperfusion injury. N. Engl. J. Med. 357, 1121–1135. 10.1056/NEJMra071667 [DOI] [PubMed] [Google Scholar]
  63. Yu L. J., Zhang K. J., Zhu J. Z., Zheng Q., Bao X. Y., Thapa S., et al. (2017). Salvianolic acid exerts cardioprotection through promoting angiogenesis in animal models of acute myocardial infarction: Preclinical evidence. Oxidative Med. Cell. Longev. 2017, 8192383. 10.1155/2017/8192383 [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Zhang L. P., Zhang J. (2010). Effects of tanshinone IIA on myocardial ischemia reperfusion injury. Chin. COMMUNITY Dr. 12, 28. [Google Scholar]
  65. Zhang Y., Wei L., Sun D., Cao F., Gao H., Zhao L., et al. (2010). Tanshinone IIA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats. Diabetes, Obes. metabolism 12, 316–322. 10.1111/j.1463-1326.2009.01166.x [DOI] [PubMed] [Google Scholar]
  66. Zheng Y. M., Yu X., Hu M. (2010). Effect of tanshinone IIA on expression of BCL一2 and caspase-3 during myocardial ischemia-reperfusion. J. HUANGSHI Inst. Technol. 26, 59–61+64. [Google Scholar]
  67. Zhou Y. P., Yang P. (2012). Expression of EPOR in ischemia-reperfusion injured myocardium and intervention effect of tanshinone II A. LIAONING J. TRADITIONAL Chin. Med. 39, 175–177. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES